# Chronic Lymphocytic Leukemia

CLL requires confirmation of persistent clonal B-cell lymphocytosis, risk assessment before therapy, and treatment only for active disease. Modern care prioritizes BTK- and BCL2-directed strategies, while surveillance remains appropriate for most asymptomatic early-stage patients.

**Clinical question:** How should clinicians confirm, risk-stratify, observe, and treat chronic lymphocytic leukemia in contemporary practice?

Updated: 2026-08-21T01:36:40.204368+00:00

## What matters in practice
- Confirm CLL with at least 5 × 10⁹/L clonal peripheral-blood B cells with characteristic immunophenotype persisting for at least 3 months; lower-count CLL-phenotype clones are monoclonal B-cell lymphocytosis unless marrow-infiltration cytopenia establishes CLL. [3][16][21]
- Do not treat asymptomatic early-stage CLL solely because of lymphocytosis; active surveillance is appropriate until symptoms or other treatment indications develop. [1][22]
- Before each new treatment course, assess del(17p) by FISH and TP53 mutation by sequencing because TP53 disruption predicts poor outcomes with chemoimmunotherapy and informs treatment selection. [19][22]
- BTK- and BCL2-directed therapies have largely replaced chemoimmunotherapy in first- and second-line CLL; regimen selection depends on treatment-duration goals, comorbidity, prior exposure, adverse-effect tolerance, and drug interactions. [18][19]

## Confirm clonal CLL and distinguish related entities

Peripheral blood testing is usually sufficient for diagnosis.

Diagnose CLL when peripheral blood contains at least 5 × 10⁹/L clonal B lymphocytes for at least 3 months with a characteristic CLL immunophenotype. Flow cytometry should demonstrate the characteristic B-cell phenotype, including CD19, CD5, CD20, CD23, and light-chain restriction. [3][16]

Below this blood clonal-B-cell threshold, classify a CLL-phenotype clone as monoclonal B-cell lymphocytosis (MBL) when there is no disease-defining marrow-infiltration cytopenia. CLL and small lymphocytic lymphoma are the same disease with different anatomic presentations and are treated similarly. [16][21]

Obtain a CBC with differential, peripheral smear, and peripheral-blood flow cytometry for suspected CLL. Routine bone marrow biopsy and routine cross-sectional or PET imaging are not required for initial diagnosis; consider marrow evaluation when cytopenias are unexplained or diagnostic uncertainty persists. [3][21]
- Use peripheral-blood flow cytometry rather than morphology alone to establish clonality and immunophenotype. [3][16]
- Do not use routine imaging to establish initial CLL diagnosis in an otherwise straightforward presentation. [21]
- Evaluate cytopenias carefully: cytopenia caused by typical marrow infiltration establishes CLL regardless of circulating B-cell count. [16]

*Diagnostic distinctions relevant to initial classification. [3][16][21]*

| Entity | Defining finding | Clinical implication |
| --- | --- | --- |
| CLL | At least 5 × 10⁹/L clonal peripheral-blood B cells with characteristic phenotype, sustained for at least 3 months. [3][16] | Stage, assess treatment need, and obtain predictive testing before therapy. [19] |
| CLL-phenotype MBL | Clonal B-cell count below 5 × 10⁹/L without disease-defining marrow-infiltration cytopenia. [21] | Periodic surveillance rather than CLL-directed treatment. [21] |
| SLL | Same biologic disease as CLL with predominant nodal presentation rather than circulating disease. [3][16] | Use the same overall treatment principles as CLL. [16] |

## Separate prognosis from treatment indication

Risk markers refine counseling and regimen selection but do not independently mandate treatment.

Stage clinically using Rai or Binet systems; iwCLL integrates Rai and Binet categories for standardized disease assessment. [20] Early-stage disease often follows a slow course, and some untreated patients have survival similar to the general population. [3][22]

Before initiating therapy, test for del(17p) by FISH and TP53 mutation by DNA sequencing. iwCLL-based recommendations support this testing because TP53-disrupted CLL has a high likelihood of poor response or early relapse after chemoimmunotherapy. [19][22] FISH using four probes and assessment of immunoglobulin heavy-chain variable-region mutation status are also recommended in contemporary guideline-based prognostic evaluation. [16]

Reassess predictive genetics before subsequent lines of therapy rather than assuming results remain clinically sufficient from the initial workup; treatment selection in relapsed disease depends on prior treatment class, reason for discontinuation, patient factors, and available trials. [17][18]
- Use Rai/Binet stage for standardized clinical risk communication, not as an automatic trigger for therapy. [20]
- Obtain del(17p) and TP53 mutation status before treatment selection. [19]
- Avoid chemoimmunotherapy as the preferred strategy for TP53-disrupted disease because of poor expected durability. [22]

## Observe until active disease requires therapy

The decision to treat is driven by active or symptomatic disease, not the diagnosis alone.

Active surveillance is appropriate for asymptomatic Rai 0-II or Binet A-B disease until symptoms or other accepted indications for treatment emerge. [1] Randomized comparisons of immediate versus delayed treatment did not show a significant long-term survival benefit from early treatment initiation in otherwise asymptomatic patients. [22]

At surveillance visits, reassess symptoms, lymphadenopathy and splenomegaly, CBC trends, and evolving cytopenias. The relevant transition is from clinically stable disease to iwCLL-defined active disease, including clinically symptomatic disease. [22][23] The supplied evidence does not provide sufficiently detailed iwCLL thresholds for cytopenias, lymphocyte kinetics, nodal bulk, or constitutional symptoms; verify current iwCLL or NCCN criteria when making a treatment-start decision. [1][15][23]
- Do not initiate therapy for isolated asymptomatic lymphocytosis. [1][22]
- Start a treatment discussion when disease becomes clinically symptomatic or otherwise meets current iwCLL active-disease criteria. [22][23]
- Continue observation for asymptomatic early-stage disease, with follow-up intensity individualized to disease tempo and clinical findings. [1][3]

## Use targeted therapy as the default systemic approach

Choice is principally between continuous BTK inhibition and fixed-duration BCL2-based treatment.

BTK inhibitors and BCL2 inhibitors have replaced chemoimmunotherapy for most patients in first- and second-line CLL. [18] Anti-CD20 monoclonal antibodies may be incorporated into targeted regimens, while chemoimmunotherapy is now reserved for selected circumstances based on molecular profile, age, and fitness. [1][18]

Continuous BTK inhibitor therapy provides ongoing disease control but generally leaves measurable residual disease detectable, and patients may ultimately discontinue because of adverse effects or relapse. Fixed-duration combination regimens can achieve undetectable measurable residual disease, although recurrence still occurs in a meaningful proportion of patients. [18] These differing treatment-duration and response-depth goals should be discussed explicitly.

The supplied sources identify the major treatment classes and broad tradeoffs but do not provide FDA-label-supported dosing, titration, renal or hepatic adjustments, contraindications, interaction management, or comparative selection among individual BTK inhibitors. Use current U.S. prescribing information and an up-to-date CLL pathway before prescribing a specific regimen.
- Consider a BTK inhibitor strategy when continuous oral disease control is acceptable. [18]
- Consider fixed-duration BCL2-based therapy when a time-limited strategy and deeper measurable residual disease response are priorities. [18]
- Individualize selection according to comorbidities, concomitant medications, treatment goals, access, and anticipated toxicity. [17]
- Recognize tumor lysis syndrome as a reported complication of targeted therapy in CLL, particularly relevant to BCL2-directed treatment planning; use regimen-specific risk mitigation from current labeling and protocols. [2]

### Role of chemoimmunotherapy

Chemoimmunotherapy has improved survival in historical first-line studies but has been displaced in most current first- and second-line settings by BTK- and BCL2-targeted therapies. [18] Its use should be exceptional and informed by molecular risk, fitness, and availability of targeted therapy. [1]

*High-level treatment-strategy tradeoffs; regimen-specific prescribing details require current labeling and specialty protocols. [1][2][17][18]*

| Strategy | Potential advantage | Key limitation or planning issue |
| --- | --- | --- |
| Continuous BTK inhibitor therapy | Effective long-term disease control. [18] | Measurable residual disease commonly persists; later relapse or discontinuation for adverse effects may occur. [18] |
| Fixed-duration BCL2-based combination therapy | Can achieve undetectable measurable residual disease. [18] | Relapse remains possible; tumor lysis syndrome planning is required with targeted therapies. [2][18] |
| Chemoimmunotherapy | May remain an option in selected circumstances. [1] | Generally replaced by BTK- and BCL2-directed therapy and is unfavorable in TP53-disrupted disease. [18][22] |

## Sequence between BTK and BCL2 pathways when feasible

Prior drug class and reason for discontinuation determine the next strategy.

After prior BTK inhibitor therapy, switching to a BCL2 inhibitor strategy, or vice versa, is a current standard approach. [18] In relapsed or refractory disease, selection should account for prior therapies, whether treatment ended because of resistance versus intolerance, comorbidities, concomitant medications, treatment goals, and clinical-trial access. [17]

There are no head-to-head trials directly comparing BTK and BCL2 inhibitors in relapsed or refractory CLL in the supplied evidence base; therefore, class sequencing remains individualized rather than algorithmically settled. [17] Patients refractory to both BTK and BCL2 inhibitor classes have no established standard therapy and should be considered for clinical trials or referral to a CLL-focused center. [18]

Allogeneic hematopoietic stem-cell transplantation is generally reserved for younger, fit, high-risk patients who have failed a pathway inhibitor and should prompt early transplant-center assessment when applicable; it is generally unsuitable for older patients when alternatives exist because of mortality risk. [17]
- Distinguish progression on therapy from treatment intolerance before choosing the next agent class. [17]
- Refer double-refractory disease for clinical trial evaluation when possible. [18]
- Consider early transplant consultation only in selected younger, fit, high-risk patients with pathway-inhibitor failure. [17]

## Monitor disease course and treatment-specific complications

Supportive care is integral because treatment is frequently prolonged and patients are often older.

During observation, monitor for evolving symptoms, organ enlargement, and CBC changes that may signal active disease. [1][22] During targeted therapy, monitor according to the selected drug's toxicity profile and label-directed laboratory requirements; targeted therapies have distinct adverse-effect profiles, and tumor lysis syndrome has been reported in treated CLL. [2]

Do not use measurable residual disease as a stand-alone reason to alter routine care outside a regimen-specific or trial-defined context based on the supplied evidence. Contemporary guidelines address measurable residual disease in clinical evaluation, and fixed-duration combinations may achieve undetectable measurable residual disease, but recurrence remains possible. [15][18]
- Use symptoms, examination findings, and CBC trends to identify transition from surveillance to active disease. [1][22]
- Apply regimen-specific tumor lysis syndrome prevention and monitoring procedures when initiating targeted therapy. [2]
- Interpret measurable residual disease in the context of the treatment strategy rather than as proof of cure. [15][18]

## Common questions

### Does an elevated absolute lymphocyte count alone require CLL treatment?

No. Asymptomatic early-stage CLL is generally managed with active surveillance, and randomized evidence has not shown a significant long-term survival advantage for immediate treatment in asymptomatic disease. [1][22]

### What testing should be obtained before initiating CLL therapy?

Obtain del(17p) testing by FISH and TP53 mutation testing by DNA sequencing before treatment. Contemporary guideline-based prognostic assessment also includes FISH testing and immunoglobulin heavy-chain variable-region mutation status. [16][19]

### Is bone marrow biopsy required to diagnose CLL?

Usually no. CBC, smear, and peripheral-blood flow cytometry establish most diagnoses. Consider marrow examination for unexplained cytopenias, possible myelodysplasia, or diagnostic uncertainty. [3][21]

### How should double-refractory CLL be managed?

There is no established standard therapy after refractoriness to both BTK and BCL2 inhibitor classes. Prioritize clinical-trial evaluation and referral to a CLL-focused center; selected younger, fit, high-risk patients may warrant early transplant-center evaluation. [17][18]

## References
1. Chronic lymphocytic leukemia - Management Approach | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/275/management-approach
2. Chronic lymphocytic leukemia - Treatment algorithm — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/275/treatment-algorithm
3. Chronic lymphocytic leukaemia - Symptoms, diagnosis and treatment | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/275
4. Obinutuzumab, acalabrutinib, and venetoclax, after an ... — www.thelancet.com — https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(22)00211-3/abstract
5. Venetoclax plus obinutuzumab therapy for front-line ... — www.thelancet.com — https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30484-8/abstract
6. Long-term efficacy of ibrutinib–venetoclax for first-line ... — www.thelancet.com — https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00485-0/abstract
7. Supplementary appendix — www.thelancet.com — https://www.thelancet.com/cms/10.1016/S1470-2045(22)00293-5/attachment/9f401a82-e9e0-415a-a219-9a9b7dbf89b1/mmc1.pdf
8. Targeting pathological ERK1/2 signaling in cancer and ... — www.cell.com — https://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(25)00189-3
9. Targeted therapies in pediatric oncology: A start — www.cell.com — https://www.cell.com/molecular-therapy-family/oncology/fulltext/S2950-3299(26)00022-6
10. Chronic Lymphocytic Leukemia - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/chronic-lymphocytic-leukemia
11. Optimizing Markers for Chronic Lymphocytic Leukemia ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/jcla.70116
12. Revolutionizing chronic lymphocytic leukemia diagnosis — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0268960X23000954
13. Implementation of International Prognostic Index with flow ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111%2Fejh.13833
14. Immunophenotypic properties association of CLL and ALL ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1658361224001161
15. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0006497120321340
16. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC) - PubMed — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/39799061
17. Clinical practice guidelines for the diagnosis and management of chronic lymphocytic leukemia in Saudi Arabia: consensus statement by an expert panel — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12847048
18. Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11803567
19. Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10818903
20. Chronic Lymphocytic Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK66035
21. Diagnosis and treatment of chronic lymphocytic leukemia: 2025 recommendations of the Brazilian Group of Chronic Lymphocytic Leukemia of the Brazilian Association of Hematology and Hemotherapy (ABHH) — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12131026
22. Chronic Lymphocytic Leukemia - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK470433
23. When and How Long to Treat Chronic Lymphocytic Leukemia? — ascopubs.org — https://ascopubs.org/doi/10.1200/EDBK-25-473656
24. Chronic lymphocytic leukemia: a clinical review — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/25461996

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.